Phio Pharmaceuticals director Deming buys shares

Available on EDGAR 11/12/2026 - 09:52 AM EST Accepted by SEC EDGAR 11/12/2026 - 09:52 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Phio Pharmaceuticals Corp. director David H. Deming reported direct purchases of 6,800 common shares on November 10, 2026, at a weighted-average price of $0.8395 per share, and 5,200 shares on November 11, 2026, at a weighted-average price of $0.8380 per share. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Buyer: 12,000 shares

Net Buy 2 txns

Insider Deming David H

Role Director

Bought 12,000 shs ($10K)

Increase in Position 31.7%

Type	Security	Shares	Price	Value
Purchase	Common Stock, $.0001 par value F3, F2	5,200	$0.838	$4K
Purchase	Common Stock, $.0001 par value F1, F2	6,800	$0.8395	$6K

Holdings After Transaction: Common Stock, $.0001 par value — 49,800 shares (Direct)

Holdings Before and After: Common Stock, $.0001 par value, 37,800 to 49,800 shares (Direct)

Other Insiders: 2 other insiders reported open-market purchases of this stock in the 30 days up to this filing.

Footnotes (3)

1. F1. The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.8079 to $0.8600 per share on November 10, 2026. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
2. F2. Includes shares of common stock underlying unvested restricted stock units.
3. F3. The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.8269 to $0.8600 per share on November 11, 2026. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Key Figures

Shares purchased: 6,800 shares Weighted-average purchase price: $0.8395 per share Shares purchased: 5,200 shares +1 more

4 metrics

Shares purchased 6,800 shares November 10, 2026

Weighted-average purchase price $0.8395 per share November 10, 2026

Shares purchased 5,200 shares November 11, 2026

Weighted-average purchase price $0.8380 per share November 11, 2026

Key Terms

weighted average purchase price, unvested restricted stock units

2 terms

weighted average purchase price financial

"weighted average purchase price for the November 10 purchase"

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

unvested restricted stock units financial

"shares of common stock underlying unvested restricted stock units"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PHIO shares did director David H. Deming buy, and at what prices?

David H. Deming bought 6,800 shares on November 10, 2026, at a weighted-average $0.8395 per share, and 5,200 shares on November 11, 2026, at a weighted-average $0.8380 per share. The respective transaction price ranges were $0.8079 to $0.8600 and $0.8269 to $0.8600 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Deming David H

(Last) (First) (Middle)

C/O PHIO PHARMACEUTICALS CORP

411 SWEDELAND RD., STE 23-1080

(Street)

KING OF PRUSSIA PENNSYLVANIA 19406

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Phio Pharmaceuticals Corp. [ PHIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $.0001 par value	11/10/2026		P		6,800	A	$0.8395(1)	44,600(2)	D
Common Stock, $.0001 par value	11/11/2026		P		5,200	A	$0.838(3)	49,800(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.8079 to $0.8600 per share on November 10, 2026. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

2. Includes shares of common stock underlying unvested restricted stock units.

3. The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.8269 to $0.8600 per share on November 11, 2026. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

	/s/ Lisa C. Carson, Attorney-in-fact	11/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)